Learn more about the latest Delphi Diagnostics news and the Endocrine Activity Index (EAI) Test by reading the press releases below. EAI is known in publications as the Sensitivity to Endocrine Therapy (SET2,3) Test. Clicking on the links below will take you to the full text news pages.
Delphi DiagnosticsTM Inc Announces a Publication Showing that the Sensitivity-to-Endocrine-Therapy (SET2,3) Index had Prognostic Value that was Independent and Complementary to the 21-gene Recurrence Score (Oncotype DX®) in Node-Positive Breast Cancer
March 9, 2023
Houston, TX, March 09, 2023 – Delphi Diagnostics, Inc announces the publication entitled, “Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial,” as a new online release in the Journal of Clinical Oncology, on January 17, 2023 1. This publication of an independent analysis by the National Cancer Institute’s Southwest Oncology (SWOG) clinical trials network further establishes the SET2,3 Index as providing additional and significant prognostic information to the currently available prognostic and predictive tests to inform treatment planning for patients with hormone receptor-positive (HR+), stage II/III breast cancer. […]
Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™
October 27, 2022
Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy., […]
Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037
September 22, 2022
Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio., […]
SET2,3 Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022
June 13, 2022
For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens., […]
SET2,3 index adds independent, complementary information to personalize breast cancer treatment
December 14, 2021
Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX Recurrence Score in an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer.[…]